2,5-二乙基-4-甲基-1,3-噻唑 | 41981-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,5-二乙基-4-甲基-1,3-噻唑
• 英文名称: 2,5-diethyl-4-methylthiazole
• 英文别名: 2,5-diethyl-4-methyl-thiazole；2.5-Diaethyl-5-methyl-thiazol；4-Methyl-2,5-diaethyl-thiazol；2,5-Diethyl-4-methylthiazol；2,5-diethyl-4-methyl-1,3-thiazole
• CAS: 41981-71-9
• 化学式: C₈H₁₃NS
• 分子量: 155.264
• InChiKey: AEVBKBWVXISVBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  82-90 °C(Press: 13 Torr)
• 密度：
  1.007±0.06 g/cm3(Predicted)
• LogP：
  3.085 (est)
• 物理描述：
  Solid
• 熔点：
  87°C
• 保留指数：
  1131;1136.5

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-溴-2-戊酮 在 sodium hydroxide 、 硫化氢 、 氨 、 sulfur 作用下， 以 xylene 为溶剂， 生成 2,5-二乙基-4-甲基-1,3-噻唑
  参考文献：
  名称：

  Asinger,F. et al., Justus Liebigs Annalen der Chemie, 1964, vol. 672, p. 156 - 178

  摘要：

  DOI：

文献信息

• [EN] SULFONYLUREA DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONYLURÉE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249664A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物及其前药、药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症、自身炎症和自身免疫疾病以及癌症等炎症小体活性涉及的疾病。
• [EN] MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI<br/>[FR] DÉRIVÉS DE MANNOSE UTILES POUR LE TRAITEMENT DE PATHOLOGIES ASSOCIÉES À E. COLI ADHÉRENTS
  申请人：ENTEROME

  公开号：WO2017021549A1

  公开（公告）日：2017-02-09

  The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6 )-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO-(C1-C6 )-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

  本发明涉及式(I)的甘露糖衍生物：其中R1代表H、CO-(C1-C6)-烷基或CO-烷基芳基，Y代表单键、CH2、O、NR3、S，A代表O、NH或S，X代表H，X'代表OH或X和X'与它们相连的碳原子形成CO基团，R2代表H、线性或支链(C1-C6)-烷基或CF3，R3代表H、C1-C6烷基、CO-(C1-C6)-烷基、 或CO ，R如权利要求1中所述。式(I)的甘露糖衍生物对治疗与粘附性大肠埃希菌（AEC）存在相关的病理病变有用，特别是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；尿路感染，特别是疼痛性膀胱综合征和膀胱炎，更特别是间质性膀胱炎；肠易激综合征；代谢性疾病，如代谢性肥胖、糖尿病、高胆固醇血症；自身免疫性炎症性疾病；以及结直肠癌，特别是结肠癌。
• Use of PDE7 Inhibitors for the Treatment of Movement Disorders
  申请人：OMEROS CORPORATION

  公开号：US20140179717A1

  公开（公告）日：2014-06-26

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。该发明的一个方面是在给予多巴胺激动剂或前体（如左旋多巴）的同时给予PDE7抑制剂。在该发明的另一个方面，PDE7抑制剂可以相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病有效的药物作用的靶点而选择性地作用于PDE7。
• Antiperspirant and deodorant compositions
  申请人：The Procter & Gamble Company

  公开号：US10568825B2

  公开（公告）日：2020-02-25

  The present application relates to antiperspirant compositions comprising perfumes and sulfur-based perfume raw materials, and methods for making and using the antiperspirant compositions.

  本申请涉及包含香水和硫基香水原料的止汗剂组合物，以及制造和使用止汗剂组合物的方法。
• Fragrance materials
  申请人：The Procter & Gamble Company

  公开号：US10952951B2

  公开（公告）日：2021-03-23

  The present application relates to perfume raw materials, perfumes, perfume delivery systems and consumer products comprising such perfume raw materials, perfumes and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. The perfumes disclosed herein expand the perfume communities' options.

  本申请涉及香水原料、香水、香水输送系统和包含此类香水原料、香水和/或此类香水输送系统的消费品，以及制造和使用此类香水原料、香水输送系统和消费品的工艺。本文公开的香水扩大了香水界的选择范围。